Positron Recieves Indiana Board of Pharmacy License
FISHERS, Ind., Dec. 19, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce that on December 16, 2011, the Company received a nuclear pharmacy license from the Indiana Board of Pharmacy for the Company's Crown Point, Indiana manufacturing facility.
The Indiana Board of Pharmacy license completes the requirements necessary to amend its NRC license to allow Positron to manufacture and distribute radiochemicals and radiopharmaceuticals throughout the United States. The Company will begin to produce Indium 111 Oxyquinoline for customer evaluation and commercial sale.
"We are pleased to receive this approval as it will allow our Crown Point facility to become fully licensed and operational as a radiochemical manufacturing facility," said Scott Stiffler, Positron's Vice President of Pharmaceuticals. "The Crown Point facility provides an ideal site for the manufacturing and development of radiopharmaceuticals and radiochemicals. The revenue generated from our Indium Oxyquinoline sales will allow Positron to expand its current product offerings. I'm pleased with the team's efforts and execution at Crown Point of this significant milestone."
About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine. Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com .<